Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma

NCT01350401 is registered in ClinicalTrials.gov with Adaptimmune as lead sponsor.

NCT NCT01350401
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01350401 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma
Lead sponsor
Adaptimmune
Phase
Phase 1/2
Overall status
Terminated
Start date
June 1, 2011
Completion date
March 1, 2018
Enrollment
4 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma